StarClose™ femoral arteriotomy closure device: An advance in arterial closure

Expert Review of Medical Devices

Volumn 2, Issue 3, 2005, Pages 247-252

  Ruygrok, Peter N ^a   Chou, Tony M ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b ABBOTT VASCULAR   (United States)

Author keywords

Angioplasty; Closure; Femoral artery; Intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; SUTURE MATERIAL; TIROFIBAN;

ANGIOCARDIOGRAPHY; ARTERIOTOMY; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; DEVICE; FEMORAL ARTERY; HEMATOMA; HEMOSTASIS; HUMAN; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURGICAL EQUIPMENT; BLOOD CLOTTING DISORDER; EQUIPMENT; EQUIPMENT DESIGN; HEART SURGERY; INJURY; INSTRUMENTATION; METHODOLOGY; PUNCTURE; SURGICAL INSTRUMENT;

PHOCIDAE;

CARDIAC SURGICAL PROCEDURES; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; FEMORAL ARTERY; HEMOSTATIC TECHNIQUES; HUMANS; PUNCTURES; SURGICAL INSTRUMENTS; VASCULAR HEMOSTATIC DISORDERS;

EID: 18844414319     PISSN: 17434440     EISSN: None     Source Type: Journal    
DOI: 10.1586/17434440.2.3.247     Document Type: Review

References (21)

1. Krone RJ, Johnson L, Noto T and the Registry Committee of the Society for Cardiac Angiography and Interventions. Five-year trends in cardiac catheterization: a report from the Registry of the Society for Cardiac Angiography and Interventions. Cathet. Cardiovasc. Diagn. 39, 31-33 (1996).
2. Nikolsky E, Mehran R, Halkin A et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures. A meta-analysis. J. Am. Coll. Cardiol. 44, 1200-1209 (2004)
3. Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization - systematic review and meta-analysis. JAMA 291, 350-357 (2004).
4. Ruygrok PN, Ormiston JA, Stewart JT et al. Initial experience with a new femoral artery closure device following percutaneous coronary intervention with glycoprotein IIb/IIIa inhibition. Cathet. Cardiovasc. Intervent. (2005) (Submitted).
5. Bogart DB, Bogart MA, Miller JT et al. Femoral artery catheterization complications: a study of 503 consecutive participants. Cathet. Cardiovasc. Diagn. 34, 8-13 (1995).
6. Nasser T, Mohleri El, Wilensky R, Hathaway D. Peripheral vascular complications following coronary interventional procedures. Clin. Cardio. 18, 609-614 (1995).
7. Appelgate R, Grabarczyk M, Little W et al. Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularisation. J. Am. Coll. Cardiol. 40, 78-83 (2002).
8. Resnic F, Blake G, Ohno-Machado L et al. Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb/IIIa inhibitors. Am. J. Cardiol. 88, 493-496 (2001).
9. Waksman R, King III SB, Douglas JS et al. Predictors of groin complications after balloon and new-device coronary intervention. Am. J. Cardiol. 75, 886-889 (1995).
10. Omoigui N, Califf R, Pieper K et al. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). J. Am. Coll. Cardiol. 26, 922-930 (1995).
11. Christensen B, Lacarella C, Manion R et al. Sandbags do not prevent complications after catheterization. Circulation 90, 1-205 (1994).
12. Pracyk JB, Wall, TC, Longabaugh JP et al. A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention. Am. J. Cardiol. 81, 970-976 (1998).
13. Cragg AH, Nakagawa N, Smith TP, Berbaum KS. Hematoma formation after diagnostic angiography: effect of catheter size. J. Vasc. Interv. Radiol. 2, 231-233 (1991).
14. Kiemenej F, Laarman GJ, Oderkerken D, Slagboom T, van der Wieken R. A Randomized comparison of percutaneous transluminal coronary angioplasty by the radial, brachial and femoral approaches. J. Am. Coll. Cardiol. 29, 1269-1275 (1997).
15. Bertrand ME, Legrand V, Boland J et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting - The FANTastiC Study. Circulation 9, 1597-1603 (1998).
16. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N. Engl. J. Med. 339, 1665-1671 (1998).
17. Dick RJ, Popma JJ, Muller DW, Burek KA, Topol EJ. In-hospital costs associated with new percutaneous coronary devices. Am. J. Cardiol. 68, 879-885 (1991).
18. Krause PB, Klein LW. Utility of a percutaneous collagen hemostasis device: to plug or not to plug? J. Am. Coll. Cardiol. 22, 1280-1282 (1993).
19. Anderson HV, Bertrand M, Whitworth HB, Sax FL, Willerson JT for the Restore Investigators. Bleeding risk with platelet inhibition using tirofiban: The Restore Trial. Circulation 94, 1-553 (1996).
20. Lincoff AM, Tcheng JE, Miller DP et al. Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3Fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials. Circulation 94(16), 1-375 (1996).
21. Exaire JE, Dauerman HL, Topol EJ et al. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. Am. Heart J. 147, 31-34 (2004).